New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Lumos Pharma to Participate in November Investor Conferences
-
Strive Health Partners with Nearly 200 Nephrology Providers Across Multiple States to Implement Innovative Medicare Kidney Care Program
-
Strive Health Partners with Nearly 200 Nephrology Providers Across Multiple States to Implement Innovative Medicare Kidney Care Program
-
Form SC 13D Eargo, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
-
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
-
MBX Biosciences Appoints James Cornelius to its Board of Directors
-
STAGE ACCESS™ Launches North America "Opening Night" Week Beginning Monday, October 26th
-
Video Telematics Leader Lytx Selects OmniSci Accelerated Analytics Platform to Help Fleets Reduce Risk and Improve Safety
-
CIT GAP Funds and The Pearl Fund Lead $3M Opportunity Zone Investment in Micronic Technologies
-
Anyscale Announces $40M in Series B Funding Led by NEA
-
Form 3 Eargo, Inc. For: Oct 15 Filed by: New Enterprise Associates 15, L.P.
-
Aetion Statement on UCSF-Led Study to Inform Drug Development for COVID-19, Future Pandemics
-
Mastercard and Stride Team Up to Bring Portable Benefits to Gig and Independent Workers
-
Alfred Closes on $42 Million in New Funding
-
Announcing Coursera for Campus Free Pricing Options and Academic Integrity Upgrades
-
Fugue Introduces Next-Generation CSPM to Prove Compliance and Eliminate Cloud Misconfiguration
-
Matroid Completes $20 Million Series B Financing to Expand into Manufacturing and Industrial IOT
-
Pancreatic Cancer Action Network Announces Groundbreaking Clinical Trial Platform Transforming Development Of Treatment Options For World's Toughest Cancer
-
Paladina Health to Acquire Healthstat, Bringing Together Two of the Nation's Leading Direct Primary Care Providers
-
Duolingo Names Jim Shelton to Board of Directors
-
Woebot Health Names Health Technology Leader Monique Levy as Chief Commercial and Strategy Officer
-
Illusive Networks Secures $24 Million in Latest Funding Round
-
Israeli cybersecurity firm Illusive raises $24 million in private round
-
UCB and Aetion Announce Agreement to Enhance Real-World Evidence Generation to Advance Value-Based Contracts
-
Form SC 13D/A Senseonics Holdings, Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform
-
Horizon Technology Finance Provides $15 Million Venture Loan Facility to Topia, a leader in Global Talent Mobility
-
Korro Bio Appoints Omar Khwaja, M.D., Ph.D. to its Board of Directors
-
D.C. Housing Authority Offers Woebot to Employees and Residents
-
Beyond Identity Taps Adam Clay as Chief Revenue Officer
-
Wall Street's IPO enemies ready one-two punch
-
Form SC 13D Metacrine, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Conviva Care Centers Teams with Strive Health to Provide Kidney Disease Care Management to Patients in South Florida
-
Monte Rosa Therapeutics Announces $96 Million Series B Financing to Advance Small Molecule-based Protein Degradation Platform
-
BioInnovation Institute partners with eight international VCs
-
Strive Health Welcomes David Thornton as Chief People Officer
-
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
-
CIT GAP Funds Makes Follow-On Investment in NOVI to Advance the Next Generation of Small-Satellites
-
Form SC 13D/A Mersana Therapeutics, Filed by: New Enterprise Associates 14, L.P.
-
Form 4 Mersana Therapeutics, For: Sep 14 Filed by: New Enterprise Associates 14, L.P.
-
H1 2020 financial results and corporate business update
-
H1 2020 financial results and corporate business update
-
DataRobot Named to Forbes’ List of Top 100 Private Cloud Companies in the World
-
Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million
-
Beyond Identity Joins ForgeRock’s Trust Network of Certified Technology Partners to Deliver Passwordless Single Sign-On and Risk-Based Authorization
-
Beyond Identity Joins ForgeRock’s Trust Network of Certified Technology Partners to Deliver Passwordless Single Sign-On and Risk-Based Authorization
-
Firms will invest more in AI after the pandemic, but delivering ROI will take skill, scale, and time
-
DataRobot Introduces Major Enhancements to Its Enterprise AI Platform
-
Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics


